Mounjaro is an FDA-approved injectable medication for managing type 2 diabetes in adults and children aged 10 and older. It works alongside diet and exercise to lower blood sugar levels, and it produces significant weight loss as a secondary effect. The same active ingredient, tirzepatide, is sold under a separate brand name (Zepbound) specifically for weight management, but Mounjaro itself is approved for diabetes.
How Mounjaro Works
Most diabetes medications target a single hormone pathway. Mounjaro is different because it activates two: GIP and GLP-1. Both of these hormones are naturally released by your gut after eating, and they signal your pancreas to produce insulin. By mimicking both hormones at once, Mounjaro triggers a stronger insulin response when blood sugar is elevated and also slows digestion, reduces appetite, and helps your body use glucose more efficiently.
The dual-hormone approach is a large part of why Mounjaro outperforms older diabetes drugs. The American Diabetes Association’s 2026 treatment guidelines rank tirzepatide alongside high-dose semaglutide as having “very high” glucose-lowering power, the top tier among all available diabetes medications. It also carries no inherent risk of hypoglycemia (dangerously low blood sugar) when used without insulin or certain older medications.
Blood Sugar Reduction in Clinical Trials
In the SURPASS-1 trial, which tested Mounjaro as a standalone treatment, patients started with an average A1C of 7.9%. The highest dose brought A1C down by 2.07 percentage points, while the lowest dose reduced it by 1.87 points. The placebo group saw virtually no change. To put that in perspective, dropping A1C by two full points could take someone from poorly controlled diabetes into a near-normal range, which substantially lowers the risk of complications affecting the eyes, kidneys, and nerves.
Even the lowest dose delivered strong results. All three doses (5 mg, 10 mg, and 15 mg) achieved statistically significant reductions in both blood sugar and body weight compared to placebo.
Weight Loss as a Major Secondary Benefit
Mounjaro causes substantial weight loss in people with type 2 diabetes, and this effect is one reason it has drawn so much attention. The ADA classifies its weight-loss effect as “very high,” the strongest category among glucose-lowering medications. For many people with type 2 diabetes who also carry excess weight, this dual benefit makes Mounjaro particularly effective because weight loss itself improves insulin sensitivity and blood sugar control.
It’s worth understanding the branding distinction: Mounjaro and Zepbound contain the exact same molecule, tirzepatide. Mounjaro is the diabetes brand. Zepbound is approved separately for chronic weight management in people with obesity or overweight with a weight-related health condition, and also for obstructive sleep apnea. The two should never be used together since they are identical medications and combining them would mean double-dosing.
Heart Failure and Liver Disease Benefits
Beyond blood sugar and weight, Mounjaro is earning a role in treating related conditions. The ADA’s 2026 guidelines now recommend tirzepatide for people with type 2 diabetes, obesity, and heart failure with preserved ejection fraction, a type of heart failure where the heart pumps normally but stiffens and doesn’t fill properly. In these patients, tirzepatide has demonstrated improvements in heart failure symptoms and a reduction in heart failure events.
Observational data also suggests cardiovascular benefits more broadly. A study published in JACC: Advances found that tirzepatide use was associated with better outcomes (including lower rates of heart attack, stroke, and death) in adults aged 40 and older who had type 2 diabetes, a BMI of 25 or higher, and pre-existing heart disease.
For fatty liver disease, now called metabolic dysfunction-associated steatotic liver disease (MASLD), the ADA guidelines recommend considering tirzepatide for people with type 2 diabetes and overweight who also have this condition. A large Phase 3 trial enrolling 4,500 adults is currently testing whether tirzepatide can prevent serious liver outcomes like progression to cirrhosis and liver transplantation.
How the Dosing Schedule Works
Mounjaro is a once-weekly injection you give yourself, typically in the abdomen, thigh, or upper arm. Everyone starts at 2.5 mg for at least four weeks. This starting dose is specifically for letting your body adjust and is not expected to provide full blood sugar control on its own. After four weeks, your dose can increase by 2.5 mg increments, up to a maximum of 15 mg, based on how your blood sugar responds and how well you tolerate the medication.
Common Side Effects
Most side effects are digestive, especially during the first weeks and after dose increases. Nausea is the most frequently reported, affecting up to 18% of patients. Diarrhea occurs in up to 17%, reduced appetite in up to 11%, indigestion in up to 8%, constipation in up to 7%, and stomach pain in up to 6%. Vomiting affects up to 9% of patients. These symptoms typically improve as your body adjusts to each dose level, which is why the gradual dose increase matters.
Low blood sugar is generally not a concern with Mounjaro alone, but it becomes more common when combined with insulin (14% to 19% of patients) or sulfonylureas (10% to 14%). Serious but rare side effects include pancreatitis and gallstones, each occurring in less than 1% of patients. Severe allergic reactions are uncommon, reported in about 3% of patients.
Who Should Not Take Mounjaro
Mounjaro is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma, a rare type of thyroid cancer, or a condition called Multiple Endocrine Neoplasia syndrome type 2. It is also not appropriate for anyone who has had a serious allergic reaction to tirzepatide or any of its inactive ingredients. Mounjaro is not approved for type 1 diabetes.